Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899285 | 0.85 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL18215491 | 0.79 | — | — | |
| SCHEMBL9900646 | 0.78 | L3MBTL1 (0.36) | MEN1KMT2AL3MBTL1POLBTDP1 | |
| SCHEMBL18667339 | 0.75 | — | — | |
| SCHEMBL28477655 | 0.74 | CYP2A6 (0.36) | CYP2C19KDM4E | |
| SCHEMBL28483163 | 0.74 | PRMT6 (0.37) | CYP2C9CYP2C19LMNA | |
| SCHEMBL6864414 | 0.72 | — | — | |
| SCHEMBL9051664 | 0.72 | — | — | |
| SCHEMBL4686294 | 0.72 | — | — | |
| SCHEMBL3230379 | 0.72 | FDPS (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964547-A | Urea compound and application thereof as Sigma2 and 5HT2A dual-target inhibitor | 瀚远医药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024067304-A1 | COMPOUND WITH INHIBITORY ACTIVITY AGAINST SIGMA2 AND 5HT2A AND USE | 瀚远医药有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-103261194-B | Oxazolyl-methyl ether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-24 | — | — | CN | disclosed |
| EP-2649068-B1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8846733-B2 | Oxazolyl-methylether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2649068-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-03 | — | — | US | disclosed |
| CN-103261194-A | Oxazolyl-methyl ether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2013-08-21 | — | — | CN | disclosed |
| WO-2012077049-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
| EP-1554274-B1 | 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | GLAXO GROUP LTD (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-7304087-B2 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LIMITED (GB) | 2007-12-04 | — | — | US | disclosed |
| US-7304087-B2 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LIMITED (GB) | 2007-12-04 | — | — | US | disclosed |
| US-7304087-B2 | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LIMITED (GB) | 2007-12-04 | — | — | US | disclosed |
| US-20060258720-A1 | 1-Acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| CN-1732165-A | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | GLAXO GROUP LTD (GB) | 2006-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258720-A1 | 1-Acyl-pyrrolidine derivatives for the treatment of viral infections | HAVCR2, LIPC, ACADVL | MEN1 4800/4885KMT2A 3914/4885L3MBTL1 1097/4885 |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX7, ADORA3, P2RX1 | MEN1 2927/4885KMT2A 1166/4885L3MBTL1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.